Page 67 - IJB-10-6

International Journal of Bioprinting Semi-solid extrusion for pediatric medicine

Conflict of interest doi: 10.2471/BLT.22.288137
The authors declare they have no competing interests. 8. Mfoafo KA, Omidian M, Bertol CD, Omidi Y, Omidian
H. Neonatal and pediatric oral drug delivery: Hopes and
Author contributions hurdles. Int J Pharm. 2021;597:120296.
doi: 10.1016/j.ijpharm.2021.120296
Conceptualization: Thomas Cerveto, Roseline Mazet, 9. Alessandrini E, Brako F, Scarpa M, et al. Children’s
Maxime Annereau, Luc Choisnard preferences for oral dosage forms and their involvement
Writing – original draft: All authors in formulation research via EPTRI (European Paediatric
Writing – review & editing: All authors Translational Research Infrastructure). Pharmaceutics.
2021;13(5):730.
Ethics approval and consent to participate doi: 10.3390/pharmaceutics13050730

Not applicable. 10. Jîtcă CM, Jîtcă G, Ősz BE, Pușcaș A, Imre S. Stability of oral
liquid dosage forms in pediatric cardiology: a prerequisite
Consent for publication for patient’s safety—a narrative review. Pharmaceutics.
2023;15(4):1306.
Not applicable. doi: 10.3390/pharmaceutics15041306
11. Batchelor HK, Marriott JF. Formulations for children:
Availability of data problems and solutions. Br J Clin Pharmacol.
None. 2015;79(3):405-418.
doi: 10.1111/bcp.12268
References 12. Litalien C, Bérubé S, Tuleu C, et al. From paediatric
formulations development to access: Advances made
1. Rocchi F, Tomasi P. The development of medicines for and remaining challenges. Br J Clin Pharmacol.
children. Part of a series on Pediatric Pharmacology, guest 2022;88(10):4349-4383.
edited by Gianvincenzo Zuccotti, Emilio Clementi, and doi: 10.1111/bcp.15293
Massimo Molteni. Pharmacol Res. 2011;64(3):169-175. 13. US Food and Drug Administration. Qualifying for pediatric
doi: 10.1016/j.phrs.2011.01.016
exclusivity under Section 505A of the Federal Food,
2. O’Brien F, Clapham D, Krysiak K, et al. Making medicines Drug, and Cosmetic Act: frequently asked questions on
baby size: the challenges in bridging the formulation gap in pediatric exclusivity (505A). The Pediatric “Rule,” and their
neonatal medicine. Int J Mol Sci. 2019;20(11):2688. Interaction. Q1–Q14: Exclusivity.
doi: 10.3390/ijms20112688 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DevelopmentResources/ucm077915.htm.
3. Kogermann K, Lass J, Nellis G, Metsvaht T, Lutsar I.
Age-appropriate formulations including pharmaceutical 14. US Food and Drug Administration. Pediatric Research
excipients in neonatal medicines. Curr Pharm Des. Equity Act of 2003.
2017;23(38):5779-5789. 15. Regulation (EC) No 1901/2006 of the European Parliament
doi: 10.2174/1381612823666170926122613
and of the Council of 12 December 2006 on medicinal
4. Nunn T, Williams J. Formulation of medicines for children. products for paediatric use and amending Regulation (EEC)
Br J Clin Pharmacol. 2005;59(6):674-676. No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC
doi: 10.1111/j.1365-2125.2005.02410.x and Regulation (EC) No 726/2004.
5. Ranmal SR, Cram A, Tuleu C. Age-appropriate and 16. Regulation (EC) No 1902/2006 of the European Parliament
acceptable paediatric dosage forms: insights into end-user and of the Council of 12 December 2006 amending
perceptions, preferences and practices from the Children’s Regulation 1901/2006 on medicinal products for
Acceptability of Oral Formulations (CALF) Study. Int J paediatric use.
Pharm. 2016;514(1):296-307.
doi: 10.1016/j.ijpharm.2016.07.054 17. Commission, to the European Parliament, and the Council.
10 years of the EU Paediatric Regulation - State of Paediatric
6. Ivanovska V, Rademaker CMA, van Dijk L, Mantel- Medicines in the EU; 2017. Accessed April 20, 2021.
Teeuwisse AK. Pediatric drug formulations: a review of https://health.ec.europa.eu/system/files/2017-11/2017_
challenges and progress. Pediatrics. 2014;134(2):361-372. childrensmedicines_report_en_0.pdf
doi: 10.1542/peds.2013-3225
18. Kaguelidou F, Ouèdraogo M, Treluyer JM, et al.
7. Joosse IR, Mantel-Teeuwisse AK, Wirtz VJ, Suleman F, van Développement des médicaments en pédiatrie: défis
den Ham HA. Missing data on accessibility of children’s existants et recommandations. Therapies. 2023;78(1):
medicines. Bull World Health Organ. 2022;100(10): 95-104.
636-642. doi: 10.1016/j.therap.2022.12.002

Volume 10 Issue 6 (2024) 59 doi: 10.36922/ijb.4063